Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Itopride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 1.00 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.80 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.80 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.78 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.65 |
| ▸ | PDE4A | P27815 | 2/20 | 0.59 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.59 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Itopride SCHEMBL554675 | 0.99 | DRD2 (0.98) | DRD2DRD3HRH3LMNAACHE | |
| Itopride SCHEMBL1650211 | 0.98 | DRD2 (0.96) | DRD2DRD3HRH3LMNAACHE | |
| SCHEMBL9815695 | 0.94 | DRD2 (0.88) | DRD2DRD3HRH3LMNAACHE | |
| SCHEMBL23731302 | 0.91 | DRD2 (0.84) | DRD2DRD3HRH3LMNAACHE | |
| Trimethobenzamide SCHEMBL6683399 | 0.89 | DRD2 (1.00) | DRD2DRD3HRH3LMNAACHE | |
| Trimethobenzamide SCHEMBL28858 | 0.89 | DRD2 (1.00) | DRD2DRD3HRH3LMNAACHE | |
| Trimethobenzamide SCHEMBL41339 | 0.88 | SMN1; SMN2 (1.00) | DRD2DRD3HRH3LMNAACHE | |
| Trimethobenzamide SCHEMBL4586062 | 0.88 | DRD2 (0.98) | DRD2DRD3HRH3LMNAACHE | |
| Trimethobenzamide SCHEMBL4586216 | 0.88 | SMN1; SMN2 (1.00) | DRD2DRD3HRH3LMNAACHE | |
| Trimethobenzamide SCHEMBL4586290 | 0.88 | DRD2 (0.98) | DRD2DRD3HRH3LMNAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1881 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4635489-A1 | COMPOSITION FOR PREVENTING OR TREATING SIDE EFFECTS OF CHOLINESTERASE INHIBITORS | Dr.Noah Biotech Inc. (KR) | 2025-10-22 | — | — | EP | claimed |
| US-20250259704-A1 | SYSTEMS AND METHODS FOR CELL-FREE ITERATIVE SITE SATURATION MUTAGENESIS AND ITS APPLICATION FOR THE DIRECTED EVOLUTION OF ENZYMES CATALYZING UNNATURAL REACTIONS | U.S. DEPARTMENT OF ENERGY | 2025-08-14 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-119518232-B | Battery diaphragm, preparation method thereof and battery | 江苏正力新能电池技术股份有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119662803-A | Application of synaptotagmin 11 as marker in preparation of products for diagnosis, auxiliary diagnosis, screening or auxiliary screening of schizophrenia | 深圳百脉得生物科技有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-119518232-A | Battery diaphragm, preparation method thereof and battery | 江苏正力新能电池技术股份有限公司 | 2025-02-25 | — | — | CN | claimed |
| EP-4473964-A1 | COMPOSITION COMPRISING BETA BLOCKER AND CHOLINESTERASE INHIBITOR FOR TREATMENT OF NEURODEGENERATIVE DISEASE | Dr.Noah Biotech Inc. (KR) | 2024-12-11 | — | — | EP | claimed |
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-11-07 | — | — | US | claimed |
| WO-2024128473-A1 | COMPOSITION FOR PREVENTING OR TREATING SIDE EFFECTS OF CHOLINESTERASE INHIBITORS | 닥터노아바이오텍 주식회사 | 2024-06-20 | — | — | WO | claimed |
| US-20240148711-A1 | COMPOSITION COMPRISING BETA BLOCKER AND CHOLINESTERASE INHIBITOR FOR TREATMENT OF NEURODEGENERATIVE DISEASE | DR.NOAH BIOTECH INC. (KR) | 2024-05-09 | — | — | US | claimed |
| US-20040013621-A1 | Transdermal delivery of antiemetics | MONASH UNIVERSITY | 2004-01-22 | — | — | US | claimed |
| US-20030225096-A1 | Compositions and methods for stimulating gastrointestinal motility | RAQUALIA PHARMA INC. (JP) | 2003-12-04 | — | — | US | claimed |
| CN-1456148-A | Use of enlerogastric dynamic medicine in preparation of colonic orientation medicinal composition | DONGFANG KAIEN MEDICAL SCIENCE (CN) | 2003-11-19 | — | — | CN | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-6548501-B2 | Composition and methods for stimulating gastrointestinal motility | PFIZER INC. | 2003-04-15 | — | — | US | claimed |
| US-20020042419-A1 | Composition and methods for stimulating gastrointestinal motility | RAQUALIA PHARMA INC. (JP) | 2002-04-11 | — | — | US | claimed |
| EP-1159964-A2 | Compositions and methods for stimulating gastrointestinal motility | Pfizer Products Inc. (US) | 2001-12-05 | — | — | EP | claimed |
| EP-0306827-B1 | AMIDE COMPOUNDS, PROCESS FOR PREPARING THE SAME, AND COMPOSITION FOR ACTIVATING GASTRIC MOTOR FUNCTION CONTAINING THE SAME | Hokuriku Pharmaceutical Co.,Ltd (JP) | 1991-09-04 | — | — | EP | claimed |
| US-4983633-A | Amide compounds, process for preparing the same, and composition for activating gastric motor function containing the same | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1991-01-08 | — | — | US | claimed |
| EP-0306827-A1 | Amide compounds, process for preparing the same, and composition for activating gastric motor function containing the same | Hokuriku Pharmaceutical Co.,Ltd (JP) | 1989-03-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | DRD2 2597/4885ACHE 2093/4885DRD3 1675/4885 |
| US-20240148711-A1 | COMPOSITION COMPRISING BETA BLOCKER AND CHOLINESTERASE INHIBITOR FOR TREATMENT OF NEURODEGENERATIVE DISEASE | ACHE, BACE1, CHRNB4 | DRD2 727/4885ACHE 1/4885DRD3 1419/4885 |
| US-20040013621-A1 | Transdermal delivery of antiemetics | CYP3A5, CYP3A7, CYP3A43 | DRD2 1177/4885ACHE 328/4885DRD3 1251/4885 |
| US-20030225096-A1 | Compositions and methods for stimulating gastrointestinal motility | GHSR, GHRHR, GIPR | DRD2 2700/4885ACHE 416/4885DRD3 2224/4885 |
| US-20020042419-A1 | Composition and methods for stimulating gastrointestinal motility | GHSR, GHRHR, GIPR | DRD2 2474/4885ACHE 487/4885DRD3 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.